A photo of James Geller.

Director - Liver, Kidney and Retinoblastoma Programs, Cancer and Blood Diseases Institute

Director, Advanced Cancer Therapy Network, Cancer and Blood Disease Institute

Director, Pilot Translational Core Grant Program, Center for Clinical and Translational Science and Training

Professor, UC Department of Pediatrics

513-636-6332

513-636-3549

Board Certified

My Biography & Research

Biography

James I. Geller, MD, started in the Division of Oncology at Cincinnati Children's Hospital Medical Center as an assistant professor within the UC Department of Pediatrics in 2004. Currently, he is the medical director of Liver and Renal Tumor Programs and co-director of the Retinoblastoma Program.

His primary academic interest is the development of novel therapy options for infants, children, adolescents and young adults with solid tumors. At the institutional level, he achieves this through direct patient care and by leading our teams in clinical and research efforts in my specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, he participates as a member of the Children’s Oncology Group (COG) Renal Tumor (RTC), Liver Tumor, Retinoblastoma and Central Nervous System Committees; He functions as vice chair for the RTC and liaison to the COG Developmental Therapeutics Committee (DVL) and Pediatric Preclinical Testing Program as well as chair both the RTC Developmental Therapeutics Working Group and the COG High Risk Renal Tumors Protocols including AREN1721 (focused on immunotherapy and anti-angiogenic therapy for TFE Renal Cell Carcinoma), AREN1921 (focused on relapsed and anaplastic Wilms tumor), and has drafted the next concept for study of epigenetic therapy plus chemotherapy for treatment of rhabdoid tumor. He also serves as co-chair of the COG liver tumor protocol, the Pediatric Hepatic International Tumor Trial (PHITT); AHEP1531.

It is his goal to help facilitate the development of novel therapy for young patients affected with solid tumors. Current areas of expansion include the establishment of the Translational RCC Research Initiatives including a registry for TFE RCC, and development of data harmonization and treatment optimization for relapsed pediatric liver cancers. Integration of cellular and immunotherapy, as well as novel interventional therapeutics, remains a priority.

Clinical Interests

Pediatric oncology; solid tumors; liver tumors; kidney tumors; retinoblastoma; rare tumors; intraarterial chemotherapy and intraarterial radiotherapy for treatment of select cancers

Research Interests

Liver tumors; kidney tumors; retinoblastoma; new drug development; novel interventional therapeutics: intra-arterial chemotherapy, intra-arterial radiotherapy, high intensity focused ultrasound (HIFU)

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Cancer and Blood Diseases, Kidney Tumor, Liver Tumor, Pancreas Care, Oncology, Cancer and Blood Diseases

Cincinnati Children's Blog

Hepatoblastoma in Kids

BlogCancer and Blood Diseases

Hepatoblastoma in Kids: Most Frequently Asked Questions

By James Geller, MD3/27/2019

My Locations

My Education

BA: Chemistry, Dartmouth College, Hanover, NH. 

MD: Sackler School of Medicine, Tel Aviv University, 1997.

Residency: Pediatrics, New York Medical College, 2000.

Fellowship: Pediatric Hematology/Oncology, St Jude Children's Research Hospital, 2004.

Certification: Pediatrics, 2000, 2007; Pediatric Hematology/Oncology, 2005.

My Publications

Selected Publication

Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. Ferrer, FA; Herbst, KW; Fernandez, CV; Khanna, G; Dome, JS; Naranjo, A; Mullen, EA; Geller, JI; Gratias, EJ; Shamberger, R; et al. Journal of Pediatric Urology. 2014; 10:969-973.

Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. Ferrer, FA; Herbst, KW; Fernandez, CV; Khanna, G; Dome, JS; Naranjo, A; Mullen, EA; Geller, JI; Gratias, EJ; Shamberger, R; et al. Journal of Pediatric Urology. 2014; 10:969-973.

Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Children's Oncology Group. Khanna, G; Naranjo, A; Hoffer, F; Mullen, E; Geller, J; Gratias, EJ; Ehrlich, PF; Perlman, EJ; Rosen, N; Grundy, P; et al. Radiology. 2013; 266:610-617.

Genetic predisposition to cancer: Surveillance and intervention. Perrino, M; Cooke-Barber, J; Dasgupta, R; Gener, JI. Seminars in Pediatric Surgery. 2019; 28:150858-150858.

Aggressive pediatric renal tumors. Kotagal, M; Geller, JI. Seminars in Pediatric Surgery. 2019; 28:150860-150860.

Novel therapy for pediatric and adolescent kidney cancer. Walz, AL; Fernandez, CV; Geller, JI. Cancer and Metastasis Reviews. 2019; 38:643-655.

Differentiated Thyroid Cancer in the Pediatric/Adolescent Population: Evolution of Treatment. Remiker, AS; Chuang, J; Corathers, S; Rutter, MM; Rutter, MJ; Myer, CM; Gelfand, MJ; Trout, AT; Geller, JI. Journal of Pediatric Hematology/Oncology. 2019; 41:532-536.

Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. Daw, NC; Chi, Y; Kim, Y; Mullen, EA; Kalapurakal, JA; Tian, J; Khanna, G; Geller, JI; Perlman, EJ; Ehrlich, PF; et al. European Journal of Cancer. 2019; 118:58-66.

Treatment of advanced pediatric renal cell carcinoma. Annbalavanan, M; Geller, JI. Pediatric Blood and Cancer. 2019; 66.

Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Aguado, A; Ristagno, R; Towbin, AJ; Gupta, A; Haberle, S; Qi, Z; Patel, MN; Kukreja, KU; Tiao, GM; Geller, JI. Pediatric Blood and Cancer. 2019; 66:e27510-e27510.